The field of biotechnology continues to push the boundaries of scientific innovation, and Alameda, CA, is home to some of the most pioneering companies in the industry. Known for its vibrant biotech ecosystem and proximity to top academic institutions and research hubs, Alameda has become a hotbed for groundbreaking research and innovation. In this blog, we will explore the top 10 biotech companies headquartered or operating in Alameda, highlighting their groundbreaking technologies and unwavering commitment to excellence.
Acepodia: Antibody-Cell Conjugation Therapy
Acepodia is revolutionizing the field of cancer treatment with its innovative antibody-cell conjugation therapy, particularly targeting solid tumors such as HER2-expressing cancers, including triple-negative breast cancer. Their lead clinical candidate, ACE1702, is advancing through clinical trials with promising results. By harnessing the power of biotechnology, they are developing targeted therapies that hold great promise in improving patient outcomes. Their recent expansion into solid tumor therapies has further solidified their position as a leader in oncology. Acepodia’s cutting-edge platform combines immune cell engineering with precise antibody delivery, ensuring maximum therapeutic efficacy with minimal side effects.
Scribe Therapeutics: CRISPR platform
Scribe Therapeutics is at the forefront of gene editing technology. With their advanced CRISPR platform, they are enabling precise and efficient gene editing, opening up new possibilities for treating genetic diseases. In 2025, Scribe continued to advance its proprietary CRISPR-based tools, setting a new standard for safety and efficiency in genome editing, particularly in addressing genetic disorders like Duchenne muscular dystrophy. Specific partnerships remain undisclosed. Their proprietary CRISPR-based tools are setting a new standard for safety and efficiency in genome editing, driving progress in personalized medicine.

AgeX Therapeutics: Regenerative Medicine
AgeX Therapeutics is pioneering the field of regenerative medicine with its pluripotent stem cell-derived progenitor cell lines. Through its agreement with Pluristyx, AgeX is expanding access to clinical-grade stem cells for therapeutic applications, targeting conditions such as osteoarthritis, myocardial infarction, and neurodegenerative diseases. These cutting-edge advancements have the potential to revolutionize the treatment of various age-related diseases. Their new collaborations with academic institutions in 2025 underscore their leadership in the field. AgeX’s innovative strategies focus on tissue regeneration and extending cellular health, aiming to address conditions such as osteoarthritis, cardiovascular diseases, and neurodegeneration.
AllCells: High-Quality Biological Materials
AllCells is a leading provider of high-quality biological materials, including cytokines, stem cells, and media, offering clinical-grade human samples to support drug discovery, preclinical testing, and process development. Their reliable products play a vital role in advancing research and development efforts across the biotech industry. In 2025, they introduced a new line of personalized stem cell products tailored for precision medicine. By offering researchers access to customizable cellular products, AllCells supports advancements in immunotherapy, drug development, and disease modeling.
Alveo Technologies: Diagnostic Devices
Alveo Technologies specializes in developing diagnostic devices that offer rapid and accurate results. Their innovative approach to diagnostics has the potential to transform healthcare delivery, enabling earlier detection and personalized treatment plans. In 2025, Alveo introduced advanced personal diagnostic tools like alveoair® and alveoConnect-T®, enabling patients with conditions such as COPD, asthma, and interstitial lung diseases to monitor their lung health with clinical-grade accuracy. This device leverages advanced biosensor technology to provide quick and reliable results, reducing the burden on healthcare facilities and empowering patients to monitor their health from home.
ArsenalBio: Cell Therapy Advancements
ArsenalBio focuses on engineering advanced cell therapies for cancer. Their platform leverages next-generation T-cell engineering to target solid tumors, with their lead discovery program, AB-1015, focusing on ovarian carcinoma and other difficult-to-treat cancers. ArsenalBio’s expansion to Alameda in 2025 marks a significant step forward in bringing cutting-edge cancer treatments to clinical trials. The company’s robust pipeline includes therapies designed to overcome tumor microenvironment challenges, paving the way for more effective and durable cancer treatments.
Magnetic Insight: Magnetic Particle Imaging
Magnetic Insight is transforming medical imaging with its magnetic particle imaging technology, enabling highly sensitive detection of iron oxide-labeled cells for use in immunotherapy, regenerative medicine, and cellular tracking. By offering superior imaging capabilities and precise molecular imaging, they are advancing the diagnosis and monitoring of diseases. Their recent imaging system upgrade in 2025 promises to enhance the resolution of molecular diagnostics. Magnetic Insight’s non-invasive imaging technology is particularly valuable in tracking cellular therapies and visualizing targeted drug delivery in real time.
Penumbra: Vascular/Surgical Devices
Penumbra is dedicated to developing innovative vascular and surgical devices that improve patient outcomes. Their reliable and cutting-edge solutions are used by healthcare professionals worldwide to address critical medical needs. In 2025, Penumbra unveiled a new suite of minimally invasive surgical tools designed for neurovascular applications. Their continuous innovation ensures better recovery rates and reduces risks associated with complex procedures.
Omniox develops oxygen-delivery therapeutics for hypoxia-related diseases, including glioblastoma and ischemic stroke. Their lead compound, OMX-4.80P, is being studied for its ability to enhance the effectiveness of radiation and chemotherapy. Their platform is designed to enhance oxygen transport to tissues, a critical factor in treating conditions like cancer and stroke. Omniox’s innovative approach has gained significant traction in 2025 with ongoing clinical trials. By addressing hypoxia in tumors, Omniox is unlocking the potential for improved outcomes in radiation and chemotherapy treatments.
10. Nautilus Biotechnology: Proteomics Solutions
Nautilus Biotechnology’s proteomics platform employs Protein Identification by Short-Epitope Mapping (PrISM) to study proteins at an unprecedented scale and depth, accelerating discoveries in oncology, immunology, and neurological disorders. Their work enables the discovery of biomarkers and therapeutic targets, transforming drug development. Their expanded operations in Alameda in 2025 are indicative of their commitment to advancing proteomics. With its single-molecule protein analysis technology, Nautilus is accelerating discoveries in oncology, immunology, and neurological disorders.
Conclusion
In conclusion, the field of biotechnology is thriving with innovation, and these top 10 companies in Alameda, CA, are at the forefront of this exciting industry. From groundbreaking therapeutics to advanced diagnostics and game-changing research tools, these companies are driving advancements that have the potential to transform healthcare and improve lives. Alameda’s vibrant biotech community reflects its strategic importance as a hub for scientific breakthroughs and collaborations.
